Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037492 | 0.90 | HTR1A (0.57) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL1037712 | 0.89 | HTR1A (0.56) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL1037405 | 0.88 | HTR1A (0.55) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL1038704 | 0.82 | HTR1A (0.52) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL1038736 | 0.78 | DRD2 (0.53) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL299695 | 0.78 | DRD2 (0.51) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL299572 | 0.75 | DRD2 (0.58) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL16443714 | 0.75 | HTR1A (0.59) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL30322023 | 0.75 | HTR1A (0.59) | HTR1ADRD2HTR2AHTR2CADRA1A | |
| SCHEMBL10274899 | 0.74 | DRD2 (0.61) | HTR1ADRD2HTR2AHTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20160051548-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9206167-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-8618109-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20160051548-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | HTR1A 22/4885DRD2 126/4885HTR2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.